Novartis AG ADR (NVS)vsPOMDOCTOR LIMITED American Depositary Shares (POM)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
POM
POMDOCTOR LIMITED American Depositary Shares
$0.38
+2.21%
HEALTHCARE · Cap: $50.01M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 15322% more annual revenue ($56.58B vs $366.86M). NVS leads profitability with a 23.9% profit margin vs -40.6%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
POM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Intrinsic value data unavailable for POM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Conservative balance sheet, low leverage
16.2% revenue growth
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : POM
The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : POM
The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while POM is a growth play — different risk/reward profiles.
POM is growing revenue faster at 16.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 28/100), backed by strong 23.9% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →POMDOCTOR LIMITED American Depositary Shares
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?